Insight

Nelson Dusetti: Grateful to Institut National Du Cancer for funding through the PRT-K 2024 program

YouTube.com

Sep 9, 2024, 10:07

Nelson Dusetti: Grateful to Institut National Du Cancer for funding through the PRT-K 2024 program

Nelson Dusetti shared on X:

“Grateful to Institut National Du Cancer for funding through the PRT-K 2024 program!

This support helps us study treatment resistance in pancreatic cancer, strengthening the collaboration between CRCM – Cancer Research Centre of Marseille and Paoli-Calmettes Institute.”

Additional information.
Source: Nelson Dusetti/X

Nelson Dusetii is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.

cancer CRCM - Cancer Research Centre Institut national du cancer Nelson Dusetti. OncoDaily Oncology Paoli-Calmettes Institute Predicting Med PRT-K 2024 program

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more